BioNTech SE (BNTX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Mainz, Germany. Le PDG actuel est Ugur Sahin.
BNTX a date d'introduction en bourse 2019-10-10, 6,772 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $24.73B.
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, that develops and commercializes immunotherapies targeting cancer and infectious diseases. The company's pipeline includes multiple therapeutic programs: personalized cancer vaccines (FixVac candidates), neoantigen-specific immunotherapies including Autogene cevumeran, mRNA intratumoral immunotherapies, chimeric antigen receptor T cell therapies, checkpoint immunomodulators, and monoclonal antibodies, with most candidates in clinical development stages. BioNTech also develops prophylactic vaccines for COVID-19 and influenza, along with therapies for rare diseases. The company maintains strategic collaborations with major pharmaceutical and biotechnology partners including Pfizer, Sanofi, Genentech, Regeneron, and others to advance its diverse clinical pipeline.
